Competitive inhibitor
... molecules cannot enter the active site while the
inhibitor is there, and inhibitors cannot enter the site ... vice-versa.
In noncompetitive inhibition , the
inhibitor works by occupying some other site on the enzyme. Because of this, the substrate and
inhibitor do not compete for access to the same site. ...
Active site
... but cannot be processed by the enzyme. In noncompetitive inhibition , the
inhibitor binds to the enzyme at another site, the allosteric site , and this ... inhibition , is similar to noncompetitive inhibition except that the
inhibitor can only bind the enzyme-substrate complex rather than the free enzyme.
...
Apoptosis
... by a defective death signal in a type of lung cancer cells called NCI-H460 (human non-small cell lung cancer cells). They found that the X-linked
inhibitor of apoptosis protein (XIAP) is overexpressed in H460 cells. XIAPs bind to the processed form of caspase-9, and suppress the activity of apoptotic ...
Cancer
... also has been shown to reduce risk of second primary tumors among patients with primary head and neck cancer . Finasteride , a 5-alpha reductase
inhibitor , has been shown to lower the risk of prostate cancer. Other examples of drugs that show promise for chemoprevention include COX-2 inhibitors ...
Neurotransmitter
... vesicles.
Post-synaptic effect
A neurotransmitter's effect is determined by its receptor. For example, GABA can act as a rapid or slow
inhibitor , depending on whether an ionotropic or metabotropic receptor is the target of the molecule. Small molecule transmitters tend to have consistently ...
Proton pump
...
transmembrane ATPase
active transport
cytochrome
mitochondrion
chloroplast
electron transfer chain
proton pump
inhibitor
ATP synthase
...
Selective serotonin reuptake inhibitor
... drug information database
The FDA Ban of L-Tryptophan
References
Tamam, L. and Ozpoyraz, N. (2002). Selective serotonin reuptake
inhibitor discontinuation syndrome: a review. Advances in Therapy 19(1): 17-26. ..
...